Lam Research Corporation vs DENTSPLY SIRONA Inc — how do they compare? Lam Research Corporation trades at $328.56 (market cap $389.67B), while DENTSPLY SIRONA Inc trades at $11.4 (market cap $2.31B). The key difference: Lam Research Corporation is far larger — about 168.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| LRCX | XRAY | |
|---|---|---|
Market Cap | $389.67B | $2.31B |
Sector | Technology | Health |
52-Week High | $433.33 | $14.68 |
52-Week Low | $97.03 | $9.64 |
Enterprise Value | $387.83B | $4.39B |
Dividend Yield | 0.33% | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $328.93, up 7.35% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $18.44B, net income of $5.36B (31.27% margin), and consistent earnings beats. Recent expansion into panel-level packaging and semiconductor workforce development initiatives position LRCX for continued AI-driven growth.
Outlook remains positive with 78% analyst buy ratings and $397.18 consensus price target, though elevated valuation ratios (P/E 54.06) and potential semiconductor cycle volatility present risks. The stock offers exposure to AI infrastructure growth but requires monitoring of competitive threats and capital expenditure trends.
DENTSPLY SIRONA (XRAY) trades at $11.40, down 2.23% amid ongoing revenue declines and negative profitability. The stock shows bearish technical signals with support at $11 and resistance at $12. Recent Q2 2026 earnings beat expectations with $0.52 EPS but revenue fell 4.1% year-over-year to $898 million, reflecting persistent challenges in dental markets. The company maintains a 'Hold' analyst consensus with a $11.50 price target while executing its turnaround strategy.
Investment outlook remains cautious given six consecutive quarters of revenue declines and negative net margins. The company's restructuring efforts and new CFO appointment offer potential for operational improvement, but weak European demand and competitive pressures pose significant headwinds. With debt-to-asset ratio rising to 42.88% in 2025, financial leverage adds risk to the recovery thesis.
Trailing returns across standard periods
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →